1704740-52-2 Usage
Uses
Used in Pharmaceutical Industry:
(2S)-N-[4-[3-cyano-1-[(2-methylpropyl)]indol-5-yl]oxyphenyl]pyrrolidine-2-carboxamide is used as a selective inhibitor for the metabolic kinase PFKFB3 for the development of potential therapeutic agents. The compound's ability to inhibit PFKFB3 makes it a promising candidate for the treatment of diseases associated with abnormal cellular metabolism, such as cancer and inflammatory disorders.
Used in Cancer Research:
In the field of cancer research, (2S)-N-[4-[3-cyano-1-[(2-methylpropyl)]indol-5-yl]oxyphenyl]pyrrolidine-2-carboxamide is used as a tool to study the role of PFKFB3 in tumor growth and progression. By selectively inhibiting this kinase, researchers can gain insights into the underlying mechanisms of cancer development and identify potential targets for novel anticancer drugs.
Used in Drug Development:
(2S)-N-[4-[3-cyano-1-[(2-methylpropyl)]indol-5-yl]oxyphenyl]pyrrolidine-2-carboxamide is used as a lead compound in the development of new drugs targeting PFKFB3. Its selective inhibition of this kinase can potentially lead to the creation of more effective and targeted treatments for diseases with metabolic dysregulation, such as cancer and other metabolic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1704740-52-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,0,4,7,4 and 0 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1704740-52:
(9*1)+(8*7)+(7*0)+(6*4)+(5*7)+(4*4)+(3*0)+(2*5)+(1*2)=152
152 % 10 = 2
So 1704740-52-2 is a valid CAS Registry Number.
1704740-52-2Relevant academic research and scientific papers
Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3
Boyd, Scott,Brookfield, Joanna L.,Critchlow, Susan E.,Cumming, Iain A.,Curtis, Nicola J.,Debreczeni, Judit,Degorce, Sébastien L.,Donald, Craig,Evans, Nicola J.,Groombridge, Sam,Hopcroft, Philip,Jones, Neil P.,Kettle, Jason G.,Lamont, Scott,Lewis, Hilary J.,MacFaull, Philip,McLoughlin, Sheila B.,Rigoreau, Laurent J. M.,Smith, James M.,St-Gallay, Steve,Stock, Julie K.,Turnbull, Andrew P.,Wheatley, Edward R.,Winter, Jon,Wingfield, Jonathan
, p. 3611 - 3625 (2015/05/05)
A weak screening hit with suboptimal physicochemical properties was optimized against PFKFB3 kinase using critical structure-guided insights. The resulting compounds demonstrated high selectivity over related PFKFB isoforms and modulation of the target in
